Having trouble accessing articles? Reset your cache.

Divide or conquer

How Argonaut is switching E2F1 from growth to death pathway in cancer cells

Argonaut Therapeutics Ltd. is attacking cancer by inhibiting an epigenetic regulatory protein that controls a dual role for the E2F1 pathway. By inhibiting the PRMT5 enzyme, the company’s molecules flip the pathway from growth and proliferation to apoptosis.

CSO Nick La Thangue said E2F transcription factor 1 (E2F1) is rarely active in normal cells because it is bound to retinoblastoma protein,

Read the full 605 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers